Table 3.
Secondary end points on the basis of the available patients at the end of the trial phase: low-GFR arm
| End Point | Supportive Care, n=26 | Immunosuppressive Combination, n=27 | P Value | ||
|---|---|---|---|---|---|
| Patients with Available Data, No. | End Point Value, Mean±SD or No. (%) | Patients with Available Data, No. | End Point Value, Mean±SD or No. (%) | ||
| GFR decrease ≥30 ml/min per 1.73 m2 | 24 | 1 (4) | 25 | 5 (20) | 0.18 |
| Onset of ESRD | 24 | 1 (4) | 25 | 5 (20) | 0.18 |
| Disappearance of microhematuria | 17a | 2 (12) | 17a | 5 (29) | 0.28 |
| Absolute GFR changes at month 36, ml/min per 1.73 m2 | 23 | −5.49±8.63 | 20 | −4.64±9.02 | 0.90 |
| Mean annual change in the slope of the reciprocal of serum creatinine concentration, mg/dl | 24 | −0.02±0.03 | 22 | −0.03±0.05 | 0.58 |
| Urinary protein-to-creatinine ratio at month 12, g/g | 20 | 0.80±0.49 | 18 | 0.74±0.52 | 0.37 |
| Urinary protein-to-creatinine ratio at month 36, g/g | 18 | 0.98±0.71 | 16 | 1.27±1.4 | 0.35 |
a
A total of 22 patients in the supportive care group and 24 patients in the immunnosuppressive combination therapy group had microhematuria at baseline.